Trials / Unknown
UnknownNCT02072031
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
A Randomized, Positive-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 133 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to compare the efficacy and safety profile between Anlotinib and Sunitinib in patients with advanced Renal Cell Carcinoma(RCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib p.o. qd |
| DRUG | Sunitinib maleate | Sunitinib 50 mg p.o. qd |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2014-02-26
- Last updated
- 2016-04-26
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02072031. Inclusion in this directory is not an endorsement.